Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05062759 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
NCT05062759 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 70 participants.
The verdict
NCT05062759, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous \[SC\] every 4 weeks \[Q4W\]) on antibody responses following seasonal quadrivalent influenza virus vaccination in the fall/winter 2021-2022 in the USA.
Interventions
- DRUG Placebo
- DRUG Tezepelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2022-07-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05062759
The ClinicalTrials.gov registry entry for NCT05062759 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05062759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05062759 about?
NCT05062759 is a clinical study titled "Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma". This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous \[SC\] every 4 weeks \[Q4W\]) on antibody responses following seasonal quadrivalent influenza virus vaccination in the ...
What is the current status of trial NCT05062759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2021-08-23. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT05062759?
The interventions under investigation include: Placebo (DRUG), Tezepelumab (DRUG).
Who is sponsoring clinical trial NCT05062759?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.